Clozapine (Cz) is unique in its efficacy with treatment refractory patients and its freedom from motor side effects. The present work shows that Cz, even after dopamine depletion, suppresses responses evoked via the monosynaptic glutamatergic corticostriatal pathway. In addition, Cz is effective in displacing [3H]MK-801 from striatal homogenates. These data indicate that Cz is a glutamate antagonist. It is unclear, however, if this pharmacological action could explain Cz's lack of motor effects and it's antipsychotic potency.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0304-3940(93)90370-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroprotection effects of kynurenic acid-loaded micelles for the Parkinson's disease models.
J Liposome Res
December 2024
Department of Neurology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Anti-glutamatergic agents may have neuroprotective effects against excitotoxicity that is known to be involved in the pathogenesis of Parkinson's disease (PD). One of these agents is kynurenic acid (KYNA), a tryptophan metabolite, which is an endogenous N-methyl-D-aspartic acid (NMDA) receptor antagonist. However, its pharmacological properties of poor water solubility and limited blood-brain barrier (BBB) permeability rules out its systemic administration in disorders affecting the central nervous system.
View Article and Find Full Text PDFPilot trial of perampanel on peritumoral hyperexcitability and clinical outcomes in newly diagnosed high-grade glioma.
medRxiv
April 2024
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
Article Synopsis
- The study investigated the effects of the AMPA receptor antagonist perampanel on hyperexcitability and clinical outcomes in patients undergoing surgery for high-grade glioma.
- The trial compared perampanel to standard care using levetiracetam, measuring intraoperative hyperexcitability through high-frequency oscillation (HFO) rates and tracking seizure-free outcomes and overall survival.
- Results indicated no significant difference in hyperexcitability or survival outcomes between the two treatments, leading to the early termination of the trial due to futility, while perampanel was found to be safe and well-tolerated.
4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.
Neuropharmacology
June 2024
Department of Basic and Oral Biology, FORP, Campus USP, University of São Paulo, Ribeirão Preto, Brazil. Electronic address:
Article Synopsis
- - The study tested two compounds, 4'-fluorocannabidiol (4'-F-CBD) and HU-910, to see if they could help with l-DOPA-induced dyskinesia (LID) by reducing striatal inflammation and correcting glutamate issues in mice with Parkinson's-like symptoms.
- - Results showed that only the combination of 4'-F-CBD and the TRPV1 antagonist capsazepine (CPZ) effectively reduced LID and normalized certain glutamate transporter markers, while HU-910 and other CB2 agonists were ineffective.
- - While both compounds lowered inflammation markers in the brain, they did not independently prevent LID, suggesting that anti-inflammatory properties alone are not enough
Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES).
BMC Neurol
August 2023
Department of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Background: Persisting coma is a common complication in (neuro)intensive care in neurological disease such as acute ischemic stroke, intracerebral hemorrhage or subarachnoid hemorrhage. Amantadine acts as a nicotinic receptor antagonist, dopamine receptor agonist and non-competitive N-Methyl-D-aspartate receptor antagonist. Amantadine is a long-known drug, originally approved for treatment of influenza A and Parkinson`s Disease.
View Article and Find Full Text PDFA Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome.
Sleep Sci
June 2023
Department of Neurology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Amantadine has both anti-glutamatergic and dopaminergic action and may improve restless legs syndrome (RLS). We compared the efficacy and adverse-effect profile of amantadine and ropinirole in RLS. In this randomized, open-label, 12-week flexible-dose exploratory study, RLS patients with international RLS study group severity scale score (IRLSS) > 10 were randomized to receive either amantadine(100-300mg/day) or ropinirole (0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!